好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Novel Classifications of Alexander Disease Based on MRI Phenotypes
Child Neurology and Developmental Neurology
P4 - Poster Session 4 (5:30 PM-6:30 PM)
7-055

To explore imaging phenotypes in juvenile- and adult-onset Alexander Disease (AxD).

AxD can be divided into Type I (onset <4 years) and Type II (juvenile or adult-onset) disease. The classic MRI characteristics for AxD include extensive frontally predominant white matter T2 hyperintensity, periventricular rim with high signal on T1-weighted images, basal ganglia, thalami, and brainstem abnormalities, and contrast enhancement. Type II AxD includes atypical MRI features such as brainstem, cerebellar, and spinal cord atrophy, and predominance of posterior WM abnormalities. However, further MRI phenotyping in Type II disease has not been described.

Participants in an AxD prospective natural history study with MRI scans available for analysis at the Children’s Hospital of Philadelphia were included. A neuroradiologist blinded to clinical data reviewed the baseline MRI scans for each subject and completed a detailed case report form, which included 23 variables capturing signal or tissue abnormality in distinct brain regions. Subjects were divided into imaging subtypes based on clear and recurring patterns.

The baseline scans for 57 AxD individuals (mean age 10.7 ± 16 years) were reviewed; 15 had clinical symptoms characteristic of Type II disease. Two phenotypes in this group emerged. The brainstem lesional group (N=8) had T2 hyperintensities in the brainstem in the absence of diffuse frontal disease. Basal ganglia and periventricular signal abnormalities were present but not universal. The remaining 7 subjects had predominant medullary, cerebellar, and cervical cord atrophy in the absence of other identifiable features of AxD.

MRI pattern recognition in leukodystrophies is critical for timely diagnosis and allows for targeted genetic testing.

Authors/Disclosures
Amy T. Waldman, MD (Children's Hospital of Philadelphia)
PRESENTER
Dr. Waldman has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for SwanBio. An immediate family member of Dr. Waldman has or had stock in Pfizer. The institution of Dr. Waldman has received research support from Ionis Pharmaceuticals. The institution of Dr. Waldman has received research support from Roche/Genentech. The institution of Dr. Waldman has received research support from Ionis Pharmaceuticals. The institution of Dr. Waldman has received research support from Calico. Dr. Waldman has received publishing royalties from a publication relating to health care. Dr. Waldman has received publishing royalties from a publication relating to health care.
No disclosure on file
No disclosure on file
Hannah R. Cooper (Children'S Hospital of Philadelphia) Ms. Cooper has nothing to disclose.
Arastoo Vossough, MD (University of Pennsylvania - Children'S Hospital of Philadelphia) Dr. Vossough has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Syneos Health. Dr. Vossough has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for DeepSight. Dr. Vossough has received publishing royalties from a publication relating to health care.